文献速递基础与转化研究临床试验与 GCP

同种异体人诱导多能干细胞衍生心肌细胞心肌内注射治疗晚期缺血性心力衰竭的早期随机试验

Intramyocardial injection of allogeneic human induced pluripotent stem cell-derived cardiomyocytes in advanced ischemic heart failure: an early-stage randomized trial.
PubMed 文献 · Nat Med · 2026-08-19

HEAL-CHF 试验将 20 例射血分数≤45%的晚期心力衰竭患者随机分为接受同种异体人诱导多能干细胞衍生心肌细胞心肌内注射组或不注射组,两组均行冠状动脉旁路移植术。主要终点为安全性,即术后 1–6 个月持续性室性心动过速发生率和 12 个月随访致瘤性,两组均未观察到。细胞治疗组全部 10 例在移植后 4 周内出现加速性室性自主心律,2 例发生临床显著室性心动过速(>140 bpm),经心脏复律后完全缓解。

要点

  • 两组均未观察到持续性室性心动过速或致瘤性。
  • 细胞治疗组全部 10 例出现加速性室性自主心律,多在移植后 5–7 天。
  • 2 例临床显著室性心动过速(>140 bpm)在术后 2–3 周达峰,复律后完全缓解。

核心结论

  • 同种异体人诱导多能干细胞衍生心肌细胞心肌内注射在晚期缺血性心力衰竭患者中未观察到持续性室性心动过速或致瘤性,但早期室性心律失常常见。

研究设计与样本

  • HEAL-CHF 早期随机试验,纳入 20 例晚期射血分数降低的心力衰竭患者(左心室射血分数≤45%),18 例男性、2 例女性。
  • 患者随机接受同种异体人诱导多能干细胞衍生心肌细胞心肌内注射或不注射,两组均行冠状动脉旁路移植术。
  • 主要终点为安全性,定义为术后 1–6 个月持续性室性心动过速发生率和 12 个月随访致瘤性。

主要发现

  • 两组均未观察到持续性室性心动过速或致瘤性。
  • 细胞治疗组全部 10 例患者在移植后 4 周内出现加速性室性自主心律,通常于移植后 5–7 天出现。
  • 2 例患者发生临床显著室性心动过速(>140 bpm),于术后 2–3 周达峰,经心脏复律后完全缓解。
  • 细胞移植在 6 分钟步行距离、整体心肌灌注(99mTc SPECT-CT 静息总评分)和相对室壁增厚方面较单纯冠状动脉旁路移植术显著改善。
  • 12 个月时左心室射血分数、左心室容积、心肌瘢痕大小、纽约心脏协会功能分级或明尼苏达心力衰竭生活质量问卷评分组间无显著差异。

临床怎么用

  • 该疗法目前仍处于早期试验阶段,需进一步研究确定人诱导多能干细胞衍生心肌细胞治疗的风险获益比。

局限性

  • 样本量小(n=20),为早期随机试验。
  • 观察到早期室性心律失常事件,需未来研究评估风险获益比。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A treatment for heart failure that could promote myocardial regeneration has long been sought. Here we conduct the HEAL-CHF trial (n = 20; 18 male and 2 female), in which patients with advanced heart failure with reduced ejection fraction (left ventricular ejection fraction ≤45%) were randomized to receive intramyocardial injections of allogeneic human induced pluripotent stem cell-derived cardiomyocytes or were uninjected. Both groups received concomitant coronary artery bypass grafting. The primary endpoint was safety, defined as the incidence of sustained ventricular tachycardia during the 1- to 6-month postoperative period and tumorigenicity at 12 months of follow-up. Neither sustained ventricular tachycardia nor tumorigenicity was observed in either patient group. Early post-transplantation ventricular arrhythmias occurred in patients in the cell therapy group during the first 4 weeks, as all 10 patients in this group developed accelerated idioventricular rhythm, typically emerging 5 to 7 days post-transplantation. Clinically significant ventricular tachycardia (>140 bpm), which occurred in 2 patients, peaked at 2 to 3 weeks post-procedure and resolved completely after cardioversion. Secondary efficacy analyses indicated that cell transplantation provided significantly greater improvements in 6-min walk distance, global myocardial perfusion (as assessed by the summed rest score on 99mTc single-photon emission computed tomography-computed tomography) and relative wall thickening, compared with coronary artery bypass grafting alone. No significant between-group differences were observed for left ventricular ejection fraction, left ventricular volumes, myocardial scar size, New York Heart Association functional class or Minnesota Living with Heart Failure Questionnaire scores at 12 months. In view of the arrhythmic events observed, future studies will need to determine the risk-to-benefit ratio associated with human induced pluripotent stem cell-derived cardiomyocyte therapy. ClinicalTrials.gov registration: NCT03763136 .

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Zhang H, Menasche P, Fan J, et al. Intramyocardial injection of allogeneic human induced pluripotent stem cell-derived cardiomyocytes in advanced ischemic heart failure: an early-stage randomized trial. Nat Med. 2026. PMID: 42618633. doi:10.1038/s41591-026-04605-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。